Board of Trustees of The Leland Stanford Junior University Buys New Stake in Heartflow, Inc. $HTFL

Board of Trustees of The Leland Stanford Junior University purchased a new position in shares of Heartflow, Inc. (NASDAQ:HTFL) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 312,234 shares of the company’s stock, valued at approximately $10,510,000. Heartflow accounts for about 1.2% of Board of Trustees of The Leland Stanford Junior University’s investment portfolio, making the stock its 8th largest holding.

A number of other hedge funds have also recently modified their holdings of the stock. Baillie Gifford & Co. purchased a new position in Heartflow during the third quarter valued at approximately $101,182,000. Emerald Mutual Fund Advisers Trust acquired a new stake in shares of Heartflow during the 3rd quarter worth approximately $4,418,000. Lisanti Capital Growth LLC purchased a new position in shares of Heartflow during the 3rd quarter valued at approximately $982,000. TrueMark Investments LLC acquired a new position in shares of Heartflow in the 3rd quarter valued at $918,000. Finally, New York State Common Retirement Fund purchased a new stake in Heartflow during the third quarter worth $4,015,000.

Analyst Ratings Changes

A number of research analysts have weighed in on the stock. Weiss Ratings reiterated a “sell (d)” rating on shares of Heartflow in a research report on Monday, December 29th. JPMorgan Chase & Co. upped their price target on Heartflow from $36.00 to $40.00 and gave the stock an “overweight” rating in a report on Thursday, November 13th. Canaccord Genuity Group boosted their price objective on Heartflow from $39.00 to $40.00 and gave the company a “buy” rating in a research report on Thursday, November 13th. Stifel Nicolaus increased their target price on Heartflow from $35.00 to $40.00 and gave the company a “buy” rating in a research report on Thursday, November 13th. Finally, Wells Fargo & Company started coverage on shares of Heartflow in a report on Wednesday, January 28th. They issued an “overweight” rating and a $38.00 price target for the company. Five investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $38.50.

Heartflow Stock Performance

NASDAQ:HTFL opened at $28.39 on Wednesday. Heartflow, Inc. has a 12 month low of $25.38 and a 12 month high of $41.22. The company has a 50-day moving average price of $30.59. The firm has a market capitalization of $2.42 billion and a price-to-earnings ratio of -15.69.

Insider Activity at Heartflow

In related news, Director Jeffrey C. Lightcap purchased 40,000 shares of the stock in a transaction that occurred on Tuesday, December 16th. The stock was acquired at an average price of $26.34 per share, with a total value of $1,053,600.00. Following the completion of the acquisition, the director directly owned 40,000 shares in the company, valued at approximately $1,053,600. This trade represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Heartflow Company Profile

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.